GHK-Cu vs BPC-157
How GHK-Cu and BPC-157 differ on mechanism, dosing, and the strength of the evidence behind each.
How this is graded
Every compound below carries a REGEN research grade, from S (regulatory approval behind the use it is bought for) down to F (no clinical evidence). Ordering follows that grade rather than search volume, so the compound at the top is the one with the most evidence, not the one most often sold. Doses are those reported in published protocols and are not recommendations.
GHK-Cu
GHK-Cu is a naturally occurring copper-binding tripeptide whose plasma levels decline with age. It is best known for stimulating collagen and elastin production, improving skin firmness and wound healing, and supporting hair follicle health. It also has antioxidant and anti-inflammatory properties and has been studied for gene-expression effects associated with tissue remodeling. Available both as an injectable for systemic effects and topically for skin and hair. Often part of longevity and aesthetics protocols rather than performance stacks.
BPC-157
BPC-157 is a 15-amino-acid partial sequence of body protection compound found in gastric juice. It is widely used in recovery protocols for its reported effects on tendon, ligament, muscle, and gut-lining repair. Mechanistically it is associated with upregulation of growth factor receptors and promotion of angiogenesis (new blood vessel formation), which supports tissue healing. It is frequently stacked with TB-500 for synergistic recovery and is a cornerstone of the healing-focused peptide protocol. Human clinical data is limited; most evidence is preclinical.
Evidence compared
| GHK-Cu | BPC-157 | |
|---|---|---|
| Research grade | Cgrade | Cgrade |
| Reported dose | 1–2 mg | 250–500 mcg |
| Frequency | 1x daily (injectable) | 1-2x daily |
| Half-life | ~1 hour | ~30 minutes |
| Routes | subcutaneous, topical | subcutaneous, oral, intramuscular |
| Tracked outcomes | Skin & Aesthetics, Longevity, Joint & Tendon Health | Joint & Tendon Health, Gut Health, Cognitive Function |
| Contraindications | Wilson's disease, copper sensitivity, pregnancy | active malignancy, pregnancy |
Which has more behind it
GHK-Cu and BPC-157 sit at the same research grade (C), so the choice between them turns on mechanism and tolerability rather than evidence weight. Both entries link through to the full reference, where the trial list and citations for each claim are set out in full.
Full GHK-Cu reference · Full BPC-157 reference
At a glance
| Compound | Grade | Reported dose | Half-life |
|---|---|---|---|
| GHK-Cu | Cgrade | 1–2 mg · 1x daily (injectable) | ~1 hour |
| BPC-157 | Cgrade | 250–500 mcg · 1-2x daily | ~30 minutes |
Frequently asked questions
GHK-Cu or BPC-157, which has better evidence?
GHK-Cu and BPC-157 sit at the same research grade (C), so the choice between them turns on mechanism and tolerability rather than evidence weight.
Can GHK-Cu and BPC-157 be used together?
The catalog does not list GHK-Cu and BPC-157 as a common pairing. Combining compounds does not combine their evidence.
What doses are reported for GHK-Cu?
Published protocols report 1–2 mg, 1x daily (injectable). This is what the literature describes, not a recommendation.
References
- GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration · Pickart L, Margolina A · 2018
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. · Yang ZX, He XT, Li X, Lian YS, Sun JY · 2018
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. · Miller TR, Wagner JD, Baack BR et al. · 2006
- Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. · Taylor TH, Chang CC, Elliott T, Colturato LF, Kort HI, Nagy ZP · 2008
- Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. · Fu SC, Cheuk YC, Chiu WY et al. · 2015
- The potential of GHK as an anti-aging peptide - PMC - NIH · Dou Y, Lee A, Zhu L, Morton J, Ladiges W · 2020
- Canapp SO Jr, et al. The anti-inflammatory effect of the naturally occurring peptide GHK. Veterinary Surgery. 2003;32(4):391-396. · Russell IF · 2003
- Glycyl-l-histidyl-l-lysine-Cu(2+) rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway. · Deng M, Zhang Q, Yan L et al. · 2023
- The human tri-peptide GHK and tissue remodeling · Pickart L · 2008
- Golgi-targeted copper delivery strategy via enhancing copper-dependent proteins' activity for fascia regeneration. · Wang R, Xu Y, Saiding Q et al. · 2026
- The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health - PMC · Pickart L, Vasquez-Soltero JM, Margolina A · 2012
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract · Sikiric P, et al. · 2011
- Brain-gut axis and pentadecapeptide BPC 157 · Sikiric P, et al. · 2016
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. · Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM · 2025
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. · Lee E, Padgett B · 2021
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing · McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM · 2025
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. · Lee E, Walker C, Ayadi B · 2024
- Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. · Chang CH, Tsai WC, Hsu YH, Pang JH · 2014
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. · Lee E, Burgess K · 2025
- Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats · Xue XC, Wu YJ, Gao MT, Li WG, Zhao N, Wang ZL, Bao CJ, Yan Z, Zhang YQ · 2004
- ClinicalTrials.gov. PCO-02 - Safety and Pharmacokinetics Trial.
- Pentadecapeptide BPC 157 shortens duration of tetracaine- and oxybuprocaine-induced corneal anesthesia in rats. · Mirković I, Kralj T, Lozić M et al. · 2020
- The pharmacological properties of the novel peptide BPC 157 (PL-10) · Sikiric P · 1999
- Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine. · Amic F, Drmic D, Bilic Z et al. · 2018